Epione's medication demonstrates opiate-level pain relief in clinical studies of its APIs. It is poised for submission and priority review by the FDA. Our commercialization strategy ensures that the approved medication will enter the marketplace with a significant volume of sales contracts in place. The Epione medication has the potential to reach sales of $3 billion for its two primary indications by 2020, based on our market analysis.